US Stock MarketDetailed Quotes

ANNX Annexon

Watchlist
  • 3.070
  • +0.060+1.99%
Close Feb 14 16:00 ET
  • 3.080
  • +0.010+0.33%
Post 18:45 ET
327.24MMarket Cap-2.98P/E (TTM)

About Annexon Company

Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington’s and alzheimer’s disease, multiple sclerosis, glaucoma, parkinson’s disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.

Company Profile

SymbolANNX
Company NameAnnexon
Listing DateJul 24, 2020
Issue Price17.00
Founded2011
CEOMr. Douglas Love, Esq.
MarketNASDAQ
Employees71
Fiscal Year Ends12-31
Address1400 Sierra Point Parkway,Building C,Suite 200
CityBrisbane
ProvinceCalifornia
CountryUnited States of America
Zip Code94005
Phone1-650-822-5500

Company Executives

  • Name
  • Position
  • Salary
  • Douglas Love, Esq.
  • President, Chief Executive Officer and Director
  • 2.45M
  • Jennifer Lew
  • Executive Vice President, Chief Financial Officer and Principal Accounting Officer
  • --
  • Michael Overdorf
  • Executive Vice President and Chief Business Officer
  • --
  • Dr. Jamie Dananberg, M.D.
  • Executive Vice President and Chief Medical Officer
  • --
  • Ted Yednock,PhD
  • Executive Vice President and Chief Innovation Officer
  • 1.14M
  • Dr. Dean Richard Artis, PhD
  • Executive Vice President and Chief Scientific Officer
  • 1.83M
  • Thomas G. Wiggans
  • Chairman of the Board
  • 132.43K
  • William B.J. Jones, Jr
  • Director
  • --
  • Dr. William H. Carson, M.D.
  • Independent Director
  • 103.43K
  • Jung E. Choi
  • Independent Director
  • 100.93K
  • William D. Waddill
  • Independent Director
  • 103.43K
  • Muneer A. Satter
  • Independent Director
  • 103.93K
  • Bettina M. Cockroft
  • Independent Director
  • 100.93K

Trending Stocks

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Tesla's earnings caused fluctuations, what's your market outlook?
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More